Company Filing History:
1 out of 832,891 Years Active: 2002
Title: Guy Cornelius: Innovator in Tumor Antigen Research
Introduction
Guy Cornelius is a notable inventor based in Brussels, Belgium. He has made significant contributions to the field of immunology, particularly in the isolation of cytotoxic T lymphocyte (CTL) clones. His work focuses on advancing cancer treatment through innovative methodologies.
Latest Patents
Guy Cornelius holds a patent for "Tumor antigens and CTL clones isolated by a novel procedure." This invention pertains to the isolation of CTL clones that are specific for MAGE-1 and MAGE-4. The patent describes a process involving successive steps of stimulation and testing of lymphocytes with antigen-presenting cells. These cells present antigens derived from various expression systems, including recombinant Yersinia, recombinant Salmonella, and recombinant viruses. The invention also encompasses the MAGE-1 and MAGE-4 antigenic peptides, as well as the peptide/HLA complexes recognized by the isolated CTL clones. He has 1 patent to his name.
Career Highlights
Throughout his career, Guy Cornelius has demonstrated a commitment to advancing cancer research. His innovative approaches have the potential to improve therapeutic strategies for patients suffering from cancer. His work is characterized by a blend of scientific rigor and practical application.
Collaborations
Guy has collaborated with esteemed colleagues, including Rosalie Luiten and Marie-Therese Duffour. These partnerships have enriched his research and contributed to the development of groundbreaking technologies in the field.
Conclusion
Guy Cornelius is a pioneering inventor whose work in tumor antigen research is paving the way for new cancer therapies. His contributions to the field are invaluable and reflect a dedication to improving patient outcomes through innovation.